Rakuten Medical
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$4.3m | Series A | ||
$40.0m | Early VC | ||
$15.1m | Series B | ||
$150m | Series C | ||
$134m | Series C | ||
$100m | Series C | ||
$75.0m Valuation: $500m | Series D | ||
$91.0m | Convertible | ||
* | N/A | $70.0m | Convertible |
* | $119m | Series E | |
Total Funding | €726m |
Recent News about Rakuten Medical
EditRakuten Medical is a biotechnology startup that operates in the healthcare industry, specifically in the field of cancer treatment. The company is developing a unique platform called Alluminox™, which is based on a cancer therapy known as photoimmunotherapy. This therapy was originally developed by Dr. Hisataka Kobayashi and his team from the National Cancer Institute in the United States.
The Alluminox™ platform is an investigational technology that includes a drug, a device, and other related components. Rakuten Medical's primary goal is to bring to market drugs and devices that treat various types of cancer using this platform. The company's mission is to provide an alternative solution in the fight against cancer, with the ultimate goal of conquering the disease.
Rakuten Medical aims to build a sustainable healthcare ecosystem that offers patients, regardless of their nationality or wealth, access to better cancer treatments. The company is committed to continuous innovation in order to develop and commercialize pioneering cancer treatments.
The business model of Rakuten Medical is based on the development and commercialization of its Alluminox™ platform. The company generates revenue by selling its innovative cancer treatment products to healthcare providers and patients.
Keywords: Rakuten Medical, biotechnology, healthcare, cancer treatment, Alluminox™ platform, photoimmunotherapy, drug development, device development, healthcare ecosystem, cancer research.